Pherecydes Pharma is a biotechnology company developing phage therapies for fighting bacterial infections that is headquartered in Romainville, France and was founded in 2006 by Jerome Gabard and Manuel Gea.
Funding
Series A
On December 1, 2014 Pherecydes Pharma completed their series A funding round with €1.9 million in funding from Auriga Partners.
Series B
On January 16, 2018 Pherecydes Pharma completed their series A funding round with €8.7 million in funding from Go Capital (lead investor), Omnes Capital, FaDiese, Auriga Partners, and ACE Management.
Timeline
January 15, 2018
Pherecydes Pharma raises a $10,600,000 series B round.
2006
Pherecydes Pharma was founded by Jerome Gabard and Manuel GEA.
Funding Rounds
Patents
Further Resources
Title
Author
Link
Type
Date
Biotech raises funds to help produce phage therapies for bacterial infections
epmmagazine
Web
News
Title
Author
Date
Publisher
Description
Anthony King
June 28, 2021
phys.org
Antibiotic resistant bacteria are killing more people each year, but scientists are turning to their natural virus predators to treat infections, as well as new vaccines to prevent disease.